<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737954</url>
  </required_header>
  <id_info>
    <org_study_id>S-CLIN-PROT-00006</org_study_id>
    <nct_id>NCT04737954</nct_id>
  </id_info>
  <brief_title>A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay</brief_title>
  <acronym>EMBOL1</acronym>
  <official_title>A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiraDx UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiraDx UK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with symptoms of Venous Thromboembolism (VTE) (mainly deep vein thrombosis (DVT)&#xD;
      or pulmonary embolism (PE)), the study will evaluate the agreement between the D-Dimer&#xD;
      measurements from the LumiraDx POC D-Dimer assay and a reference method, as an aid in&#xD;
      diagnosis, assessment and exclusion of DVT and PE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a performance evaluation study designed to assess the precision and accuracy of the&#xD;
      LumiraDx Point of Care (POC) D-Dimer test when used in patients presenting with symptoms of&#xD;
      Venous thromboembolism (VTE), which mainly comprises deep vein thrombosis (DVT) or pulmonary&#xD;
      embolism (PE).&#xD;
&#xD;
      The LumiraDx POC D-Dimer test is a quantitative immunoassay providing results in under 10&#xD;
      minutes. The accuracy of the LumiraDx POC D-Dimer test will be assessed using capillary whole&#xD;
      blood, venous blood, and plasma samples, by comparison to the D-Dimer results obtained from&#xD;
      the same individuals as analysed by trained laboratory professionals using a reference&#xD;
      device. The results of this study are intended to be used for regulatory filings for use as&#xD;
      an in vitro diagnostic test in the European Union (EU) and other relevant geographies.&#xD;
&#xD;
      Adult males and females presenting to the study sites with symptoms of VTE will be included&#xD;
      in the study. Approximately 1000 subjects will be recruited in total. An initial analysis&#xD;
      will be completed on the first 200 patients to determine accuracy of the LumiraDx D-Dimer&#xD;
      test versus the reference method. The study will continue until 1000 patients are recruited&#xD;
      and with a minimum of 120 confirmed VTE events, in order to complete retrospective analysis&#xD;
      using the LumiraDx D-Dimer cut-off for exclusion of VTE.&#xD;
&#xD;
      Once consent is obtained, blood tube samples will be drawn and finger-stick samples of&#xD;
      capillary blood will be taken from the subject, these will be applied directly to unique test&#xD;
      strips for immediate measurement of D-Dimer on the LumiraDx POC D-Dimer test.&#xD;
&#xD;
      The D-Dimer results obtained via the LumiraDx D-Dimer test will be used in a set of&#xD;
      comparative analyses designed to determine the performance characteristics of the test. This&#xD;
      study is an observational, cross-sectional design. As an observational study of an&#xD;
      investigative device, results obtained during the course of the study will not inform or&#xD;
      alter patient management or treatment decisions in any way.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>IVD Performance Evaluation Study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the accuracy of the LumiraDx POC D-Dimer assay when compared to a reference method in patients with suspected VTE.</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement of blood samples from patients with suspected VTE in a reference method and in the LumiraDx method to assess accuracy of the LumiraDx method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of accuracy of using the D-Dimer cut-off set by the LumiraDx D-Dimer test in excluding patients with symptoms of VTE (DVT and PE) when used in combination with the pre-probability test (Wells Score).</measure>
    <time_frame>10 months</time_frame>
    <description>Measurement of blood samples from patients with suspected VTE in the LumiraDx D-dimer assay in conjunction with pre-test probability score and final clinical outcome in order to set a clinical cut-off for the LumiraDx D-dimer assay</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Suspected VTE patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Venepuncture</intervention_name>
    <description>Venous blood draw</description>
    <arm_group_label>Suspected VTE patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fingerstick</intervention_name>
    <description>Capillary blood draw</description>
    <arm_group_label>Suspected VTE patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject is greater or equal to 18 years of age Willing and able to provide written informed&#xD;
        consent and comply with study procedures Symptoms of thromboembolic event&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        End-stage renal failure on haemodialysis Current anticoagulant therapy (Fragmin, LMWH)&#xD;
        within the last 30 days Patient has previously participated in this study Life expectancy&#xD;
        documented as &lt;30 days Haemodynamically unstable (e.g. cardiogenic shock) Patients taking&#xD;
        anticoagulant therapy (DOACS, Warfarin, Heparins etc) within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Body</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Emergency Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Craig</last_name>
    <phone>0044 1786 533232</phone>
    <phone_ext>00441786430411</phone_ext>
    <email>david.craig@lumiradx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Chadwick</last_name>
    <phone>+44(0)7917832613</phone>
    <email>dave.chadwick@lumiradx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Boyle</last_name>
    </contact>
    <investigator>
      <last_name>Adrian Boyle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alasdair Gray</last_name>
    </contact>
    <investigator>
      <last_name>Alasdair Gray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epsom and St Helier Hospitals</name>
      <address>
        <city>Epsom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Macfarlane</last_name>
    </contact>
    <investigator>
      <last_name>Rebecca Macfarlane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glsagow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan Cameron</last_name>
    </contact>
    <investigator>
      <last_name>Allan Cameron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roy Gardner</last_name>
    </contact>
    <investigator>
      <last_name>Roy Gardner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Lowe</last_name>
    </contact>
    <investigator>
      <last_name>David Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homerton NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Niven</last_name>
    </contact>
    <investigator>
      <last_name>William Niven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Bloom</last_name>
    </contact>
    <investigator>
      <last_name>Ben Bloom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Georges Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Holmes</last_name>
    </contact>
    <investigator>
      <last_name>Paul Holmes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Abdalla</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed Abdalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samer Elkhodair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Body</last_name>
    </contact>
    <investigator>
      <last_name>Rick Body</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Horner</last_name>
    </contact>
    <investigator>
      <last_name>Dan Horner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

